Major medicine moves flagged

A listing of a replacement for currently unavailable herpes treatment Zovirax, a rethink on osteoporosis treatment Protos and avoiding a decision on new buprenorphine patch strengths are among the July PBAC decisions.   

As well as the widely publicised listing of the infliximab biosimilar Inflectra, PBAC made a series of other positive recommendations.

PBAC recommended the temporary listing of aciclovir (AciVision) as an alternative to the listed but unavailable Zovirax to ensure consumer access to